Browse studies

Find your next paid study

23 recruiting studies matching your filters

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with ad…

Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung Cancer

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Mirati Therapeutics Inc.NCT04613596

Phase 1

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metasta…

NSCLC (Advanced Non-small Cell Lung Cancer)HNSCCCRC (Colorectal Cancer)+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

ALX Oncology Inc.NCT07085091

Phase 1

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity …

NSCLC (Advanced Non-small Cell Lung Cancer)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

BlossomHill TherapeuticsNCT06706076

Phase 1

An Open-Label Pilot Study Evaluating the Safety, Feasibility, and Preliminary Clinical Activity of Inhaled Cromolyn Sodium in Participants With Locally Advanced Lung Cancer

Brief Summary This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inh…

Locally Advanced Non-Small Cell Lung CancerLung Adenocarcinoma

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Carcinex IncNCT07675876

Phase 2

Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer

Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patien…

Non-Small Cell Lung CancerNSCLCAdvanced Non-Small Cell Lung Cancer+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Virginia Commonwealth UniversityNCT06731413

Phase 3

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epider…

Advanced Non-small Cell Lung Cancer, HER2 Mutation

Estimated

~$50 – $2,250

Actual pay is set by the research site.

BayerNCT06452277

Phase 1

An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monocl…

Solid Tumor, AdultMetastatic Solid TumorRefractory Cancer+4 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Sairopa B.V.NCT05856981

Phase 2

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initi…

Advanced Non-Small Cell Lung Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT07415005

Phase 2

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer

Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced No…

Non Small Cell Lung CancerCardiotoxicityLocally Advanced Non-Small Cell Lung Cancer+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Indiana UniversityNCT07761910

Phase 3

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pemb…

Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung+3 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.

PfizerNCT07222566

Phase 1

A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, he…

Advanced/Metastatic Solid TumorsBladder CancerUrothelial Carcinoma+10 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

PfizerNCT07090499